Brief: Immunogen Announces A Global, Multi-Target License And Option Agreement With Vertex For Immunogen's Adc Technology In The Development Of Novel Targeted Conditioning Agents

ImmunoGen

01/03/2023 11:35

March 1 (Reuters) - ImmunoGen Inc  IMGN.O :
    * IMMUNOGEN ANNOUNCES A GLOBAL, MULTI-TARGET LICENSE AND
OPTION
AGREEMENT WITH VERTEX FOR THE USE OF IMMUNOGEN'S ADC TECHNOLOGY
IN THE DEVELOPMENT OF NOVEL TARGETED CONDITIONING AGENTS
    * IMMUNOGEN TO RECEIVE A $15 MILLION UPFRONT PAYMENT
    * ELIGIBLE TO RECEIVE UP TO $337 MILLION IN POTENTIAL OPTION
FEES
AND MILESTONE PAYMENTS PLUS TIERED ROYALTIES ON A PER TARGET
BASIS
    * VERTEX IS RESPONSIBLE FOR ALL RESEARCH, DEVELOPMENT, AND
COMMERCIALIZATION AND RELATED COSTS

Source text for Eikon:  ID:nBw7QrXCla 
Further company coverage:  IMGN.O